Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

BMO Capital on SAGE Therapeutics (SAGE): 'Another Important Milestone Achieved with Brexanolone Filing for PPD'April 23, 2018 10:23 AM Sage Therapeutics (SAGE) Weakness is a Buying Opportunity - RBCApril 23, 2018 10:20 AM Sage Therapeutics Submits New Drug Application to U.S. FDA for Intravenous Brexanolone in the Treatment of Postpartum DepressionApril 23, 2018 7:00 AM